Workflow
滚动市盈率
icon
Search documents
奥美医疗收盘上涨1.10%,滚动市盈率16.13倍,总市值58.26亿元
Sou Hu Cai Jing· 2025-07-24 09:30
Group 1 - The core viewpoint of the news highlights the current financial performance and market position of Aomei Medical, indicating a low PE ratio compared to the industry average [1][3] - As of July 24, Aomei Medical's stock closed at 9.2 yuan, with a PE ratio of 16.13, marking a 76-day low, and a total market capitalization of 5.826 billion yuan [1] - The medical device industry has an average PE ratio of 54.55, with Aomei Medical ranking 34th among its peers [1] Group 2 - Aomei Medical specializes in the research, production, and sales of medical consumables, disposable medical devices, infection protection products, and home care products [2] - The company has received multiple accolades, including being listed among the top 100 private manufacturing enterprises in Hubei and recognized for its intelligent manufacturing projects [2] - In the first quarter of 2025, Aomei Medical reported a revenue of 759 million yuan, a year-on-year increase of 1.64%, while net profit decreased by 7.86% to 86.5 million yuan [3]
亚钾国际收盘下跌1.82%,滚动市盈率23.39倍,总市值293.29亿元
Sou Hu Cai Jing· 2025-07-24 08:43
Group 1 - The core viewpoint of the news is that Yara International's stock has experienced a decline, with a current price of 31.74 yuan and a rolling PE ratio of 23.39 times, which is below the industry average of 26.28 times [1][2] - Yara International's market capitalization stands at 29.329 billion yuan, ranking 16th in the fertilizer industry based on PE ratio [1][2] - The company has seen a net outflow of main funds amounting to 50.21 million yuan on July 24, with a total outflow of 220.81 million yuan over the past five days [1] Group 2 - Yara International's main business includes potassium salt mining, potassium fertilizer production, and sales, with key products being potassium chloride and brine [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 1.213 billion yuan, a year-on-year increase of 91.47%, and a net profit of 384 million yuan, a year-on-year increase of 373.53%, with a gross profit margin of 54.12% [1]
厦门港务收盘上涨1.46%,滚动市盈率33.33倍,总市值61.79亿元
Jin Rong Jie· 2025-07-24 08:35
Core Viewpoint - Xiamen Port Authority's stock closed at 8.33 yuan, up 1.46%, with a rolling PE ratio of 33.33, marking a new low in 28 days, and a total market capitalization of 6.179 billion yuan [1] Company Summary - Xiamen Port Authority's main business segments include bulk cargo handling and storage, port logistics services, and port trade [1] - The company's primary products consist of bulk cargo handling, tugboat services, agency services, sea-rail intermodal transport, cargo inspection and quarantine, trucking services, maritime express, cross-border e-commerce logistics, warehousing, and port trade [1] - For Q1 2025, the company reported operating revenue of 4.328 billion yuan, a year-on-year decrease of 31.65%, and a net profit of 630.931 million yuan, down 18.46%, with a gross profit margin of 4.73% [1] Industry Summary - The average PE ratio for the shipping and port industry is 15.23, with a median of 16.68, positioning Xiamen Port Authority at 30th place in the industry ranking [2] - The company's PE (TTM) is 33.33, while the static PE is 30.94, and the price-to-book ratio is 1.23 [2] - The total market capitalization of Xiamen Port Authority is 6.179 billion yuan, compared to the industry average market capitalization of 29.867 billion yuan and the median of 14.165 billion yuan [2]
伟思医疗收盘下跌6.18%,滚动市盈率37.27倍,总市值42.27亿元
Sou Hu Cai Jing· 2025-07-23 13:28
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Weisi Medical, which closed at 44.14 yuan, down 6.18%, with a rolling PE ratio of 37.27 times and a total market capitalization of 4.227 billion yuan [1][2] - The average PE ratio for the medical device industry is 53.52 times, with a median of 37.14 times, placing Weisi Medical at the 76th position in the industry ranking [1][2] - As of March 31, 2025, Weisi Medical has 5,933 shareholders, an increase of 637 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Weisi Medical specializes in the research, production, and sales of medical devices, with key products including magnetic stimulation, electrical stimulation, electrophysiology, consumables and accessories, and laser radiofrequency [1] - In the latest quarterly report for Q1 2025, the company achieved a revenue of 95.9127 million yuan, a year-on-year increase of 9.40%, and a net profit of 33.2201 million yuan, reflecting a year-on-year growth of 52.71%, with a gross profit margin of 66.65% [1]
振德医疗收盘上涨2.53%,滚动市盈率16.05倍,总市值58.27亿元
Sou Hu Cai Jing· 2025-07-23 12:30
Core Viewpoint - Zhendermedical's stock closed at 21.87 yuan, up 2.53%, with a rolling PE ratio of 16.05, marking a new low in 75 days, and a total market value of 5.827 billion yuan [1] Company Summary - Zhendermedical specializes in the research, production, and sales of medical and health products, focusing on basic care, surgical infection control, pressure treatment and fixation, stoma and modern wound care, and infection control protection [1] - The company has received multiple technical awards, including provincial key enterprise research institutes and high-tech enterprise certifications, and has passed the national high-tech enterprise review [1] - For Q1 2025, Zhendermedical reported revenue of 999.2 million yuan, a year-on-year increase of 2.87%, and a net profit of 51.2419 million yuan, a year-on-year decrease of 30.19%, with a gross profit margin of 34.28% [1] Industry Summary - The average PE ratio for the medical device industry is 53.52, with a median of 37.14, placing Zhendermedical at 36th in the industry ranking [2] - The industry average and median PE ratios indicate a higher valuation compared to Zhendermedical's current PE ratio of 16.05 [2] - The total market value of Zhendermedical is 5.827 billion yuan, which is significantly lower than the industry average market value of 111.58 billion yuan [2]
华人健康收盘上涨2.78%,滚动市盈率39.17倍,总市值59.20亿元
Jin Rong Jie· 2025-07-23 10:36
Core Viewpoint - The company, Huaren Health, has shown a positive financial performance with significant growth in revenue and net profit, despite a relatively high PE ratio compared to the industry average [1][2]. Group 1: Financial Performance - For the fiscal year 2024, the company achieved a record revenue of 4.532 billion yuan, representing a year-on-year growth of 19.34% [1]. - The net profit attributable to the parent company was 138 million yuan, an increase of 20.09% compared to the previous year [1]. - The net profit after deducting non-recurring gains and losses was 129 million yuan, reflecting a growth of 21.81% year-on-year [1]. - In the latest quarterly report for Q1 2025, the company reported a revenue of 1.267 billion yuan, which is a year-on-year increase of 14.71% [2]. - The net profit for Q1 2025 was 61.22 million yuan, showing a year-on-year growth of 28.15% [2]. - The operating cash flow has shown continuous improvement, indicating a steady enhancement in operational quality [1]. Group 2: Market Position and Valuation - As of July 23, the company's stock closed at 14.8 yuan, with a PE ratio of 39.17, marking a new low in 17 days [1]. - The total market capitalization of Huaren Health is 5.92 billion yuan [1]. - In comparison to the pharmaceutical retail industry, the average PE ratio is 42.87, while the median is 29.04, placing Huaren Health at the 22nd position within the industry [1]. - The company has two institutional investors holding a total of 7700 shares, with a market value of 0.00 billion yuan [1].
艾德生物收盘上涨1.28%,滚动市盈率32.95倍,总市值92.64亿元
Sou Hu Cai Jing· 2025-07-23 10:22
7月23日,艾德生物今日收盘23.66元,上涨1.28%,滚动市盈率PE(当前股价与前四季度每股收益总和 的比值)达到32.95倍,创86天以来新低,总市值92.64亿元。 从行业市盈率排名来看,公司所处的医疗器械行业市盈率平均53.52倍,行业中值37.14倍,艾德生物排 名第69位。 资金流向方面,7月23日,艾德生物主力资金净流入952.49万元,近5日总体呈流出状态,5日共流出 4540.36万元。 最新一期业绩显示,2025年一季报,公司实现营业收入2.72亿元,同比16.63%;净利润9047.18万元, 同比40.92%,销售毛利率83.48%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13艾德生物32.9536.354.8392.64亿行业平均 53.5248.844.67111.58亿行业中值37.1437.112.5651.72亿1九安医疗10.9411.060.86184.59亿2英科医疗 12.7713.771.14201.84亿3新华医疗15.2014.091.2497.43亿4奥美医疗15.9515.631.6457.63亿5山东药玻 15.9516.001.8315 ...
麦克奥迪收盘下跌2.29%,滚动市盈率52.23倍,总市值85.94亿元
Sou Hu Cai Jing· 2025-07-23 10:04
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of MacAudie, indicating a decline in stock price and a high PE ratio compared to industry averages [1][2] - As of July 23, MacAudie's stock closed at 16.61 yuan, down 2.29%, with a rolling PE ratio of 52.23 times and a total market capitalization of 8.594 billion yuan [1] - The average PE ratio for the electrical equipment industry is 38.92 times, with a median of 40.68 times, placing MacAudie at the 102nd position within the industry [1][2] Group 2 - As of the first quarter of 2025, only one institution holds shares in MacAudie, which is a fund with a total holding of 74,200 shares valued at 0.01 billion yuan [1] - MacAudie's main business includes the production and sales of epoxy insulation parts, optical microscopes, molds, medical testing products, and the provision of medical diagnostic services and energy internet technology research and operations [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 316 million yuan, a year-on-year increase of 5.91%, and a net profit of 34.8816 million yuan, a year-on-year increase of 9.70%, with a gross profit margin of 41.77% [1]
联泓新科收盘下跌1.03%,滚动市盈率85.78倍,总市值218.23亿元
Sou Hu Cai Jing· 2025-07-23 09:38
Company Overview - Lianhong New Materials Technology Co., Ltd. specializes in the research, production, and sales of advanced polymer materials and specialty fine materials [2] - The main products include EVA, VA, UHMWPE, PLA, electronic specialty gases, PP, EO, EOD, and EC [2] - The company has received multiple accolades, including being listed in the "2024 China Brand Value Evaluation Information List" and the "2024 Top 100 New Materials Companies in China" [2] Financial Performance - For Q1 2025, the company reported a revenue of 1.539 billion yuan, representing a year-on-year increase of 3.48% [2] - The net profit for the same period was 71.41 million yuan, showing a year-on-year growth of 38.83% [2] - The sales gross margin stood at 18.77% [2] Market Position - As of July 23, the company's stock closed at 16.34 yuan, with a rolling price-to-earnings (PE) ratio of 85.78 times [1] - The average PE ratio for the chemical products industry is 49.84 times, with a median of 43.43 times, placing Lianhong New Materials at the 138th position in the industry ranking [1][3] - The total market capitalization of the company is 21.823 billion yuan [1] Capital Flow - On July 23, the company experienced a net outflow of 15.6021 million yuan in principal funds, with a total outflow of 17.4334 million yuan over the past five days [1]
通源石油收盘下跌1.47%,滚动市盈率60.15倍,总市值31.54亿元
Sou Hu Cai Jing· 2025-07-23 09:38
Group 1 - The core viewpoint of the articles indicates that Tongyuan Petroleum's stock is currently underperforming with a closing price of 5.36 yuan, down 1.47%, and a rolling PE ratio of 60.15 times, significantly higher than the industry average of 29.78 times [1][2] - The company's total market capitalization is reported at 3.154 billion yuan, ranking 19th in the industry based on PE ratio [1][2] - In terms of capital flow, Tongyuan Petroleum experienced a net outflow of 42.45 million yuan on July 23, with a total outflow of 59.96 million yuan over the past five days [1] Group 2 - Tongyuan Petroleum's main business focuses on providing comprehensive solutions and technical services for oil and gas field development, with key products including perforation sales and other oilfield services [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating revenue of 258 million yuan, representing a year-on-year increase of 13.21%, while net profit was 782,700 yuan, reflecting a significant decline of 80.38% [1] - The company's gross profit margin stands at 22.53% [1]